VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / October 18, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)( FSE:4XT) ("XPhyto" or the "Company") is pleased to report the results of its ...
Review the side-effects of Rotigotine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
SAN DIEGO -- The rotigotine patch (Neupro) appeared to objectively improve sleep quality in patients with Parkinson's disease with self-reported sleep complaints, Italian researchers said here. Based ...
Researchers conducted a randomized clinical trial to assess whether 24 weeks of treatment with rotigotine can modify cognitive functions in patients with mild to moderate Alzheimer disease. Although ...
BRUSSELS, July 28 UCB today announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® ...
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / October 11, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a product ...
Sixteen patients fulfilling the inclusion criteria were prospectively enrolled in the trial. Patient demographics are presented in Table 1, and lesion maps are shown in Fig. 2. Compliance with the ...
VANCOUVER, BC / ACCESSWIRE / February 13, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT) is pleased to report an update on its commercialization plan for its ...
January 10, 2007 — Transdermal rotigotine, a dopamine agonist, is effective in controlling symptoms of early-stage Parkinson's disease (PD), a new study suggests. The multicenter, randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results